Pgm #24: Future: Non-invasive Testing for Rejection?

AlloMap Molecular Expression Testing: The Future: Non-invasive Testing for Rejection?” Alesha Luxon, an XDx representative, speaks about this new technology for non-invasive risk assessment of organ transplant rejection. While currently approved only for use in heart transplantation, she offers insight into what the future for testing may look like for wider use. For heart recipients this has been an exciting major advance already in use in our Philadelphia heart transplant centers, a simple blood draw test for rejection. Special addition: Following the above presentation, Alesha will give a second presentation on the recently released new ISHLT Guidelines for the Care of Heart Transplant Recipients.